Plotted by close date where disclosed, otherwise announcement. Select any marker to jump to the deal entry.
Three patterns show up across TransMedics's deal book — what the team buys, how it pays, and how it integrates. The patterns are the throughline; the deals below are the evidence.
2 acquisitions. Each entry carries the deal value, financing structure, target revenue, executive commentary, and the original SEC filing — the evidence behind the patterns above.
Summit was a charter flight operator based in Bozeman, Montana. Its acquisition (together with Northside Property Group, LLC) let TransMedics establish TransMedics Aviation as the first integrated national provider of air logistics dedicated exclusively to organ transplantation in the U.S., adding aviation transportation services to its National OCS Program (NOP). The deal also conveyed a 20-year operating lease at Bozeman Yellowstone International Airport, where TransMedics is constructing a commercial aircraft hangar. approximately $14.9 million preliminary purchase consideration ($18.0 million upfront cash, net of cash acquired and working capital adjustments).
We are delighted to complete the acquisition of Summit Aviation, which represents a critical element of TransMedics strategy to build and manage a national transplant logistics network designed to expand the reach and coverage of the National OCS Program (NOP). I want to take this opportunity to welcome the Summit team to the TransMedics team. I also want to welcome Ben Walton in his new role as VP of Aviation Services.Waleed Hassanein — MD, President and Chief Executive Officer, TransMedics
TransMedics FY23 10-K: "On August 16, 2023, the Company acquired Summit Aviation, Inc. and Northside Property Group, LLC ... Summit was a charter flight operator based in Bozeman, Montana. The acquisition enabled TransMedics to add aviation transportation services to its NOP and become a comprehensive national provider of donor organ retrieval and delivery in the United States."
On August 2, 2023, TransMedics acquired certain assets related to lung and heart perfusion technology from Bridge to Life Ltd. and its subsidiary Tevosol, Inc. (together BTL). The purchase was accounted for as an asset acquisition because substantially all of the fair value of the gross assets acquired was concentrated in a single set of identifiable activities consisting of the lung and heart perfusion technology, treated as an in-process research and development (IPR&D) asset. Given the early stage of development, the $27.2 million IPR&D value was expensed as research and development expense. $27.2 million in-process research and development (IPR&D) asset value, expensed as R&D; accounted for as an asset acquisition.
On August 2, 2023, the Company acquired certain assets related to lung and heart perfusion technology from Bridge to Life Ltd. and its subsidiary Tevosol, Inc., together ("BTL"). The Company intends to further develop these technologies to expand its product offerings and indications for organ transplantation.TransMedics FY23 10-K — Business Combinations and Asset Acquisition note
TransMedics FY23 10-K, Item 1A Risk Factors: "Further development of the assets we acquired from Bridge to Life, or the Bridge to Life Assets, will require extensive clinical development, management of nonclinical, clinical and manufacturing activities."